We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mast Group Launches MAST ISOPLEX CRE-Art Kit for Rapid Molecular Detection of Carbapenemase Producing Organisms

By LabMedica International staff writers
Posted on 23 Dec 2019
Mast Group Ltd. More...
(Liverpool, UK) announced the expansion of its molecular product portfolio with the launch of the new MAST ISOPLEX CRE-ART kit for the rapid molecular detection of carbapenemase producing organisms (CPOs).

Mast is a manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing. The company manufactures microbiology and molecular biology products, as well as other infectious disease and autoimmune diagnostics, using a variety of technologies.

The new MAST ISOPLEX CRE-ART is a loop mediated isothermal amplification (LAMP) kit for the detection and characterization of the seven most prevalent carbapenemase families: OXA-48, OXA-23, OXA-24/40, KPC, VIM, NDM and IMP. With ready-to-use with lyophilised pellets containing all primers and reagents, it provides rapid results with a 15-minute hands on time and a 30-minute run time. MAST ISOPLEX CRE-ART uses LAMP to provide an alternative to PCR technologies for the molecular detection of CPOs to make testing accessible to laboratories with limited resource and experience.

The company’s additional related MAST products include MAST CARBA PAcE – a rapid, simple and cost-effective solution for carbapenemase detection in Pseudomonas, Acinetobacter and Enterobacterales; MASTDISCS Combi ESBL Set (EUCAST) – with new recommended disc potencies as highlighted by EUCAST; MASTDISCS Combi AmpC, ESBL & Carbapenemase Detection Set - a combination six disc system that has been developed for the detection of Gram-negative resistance in Enterobacterales; MASTDISCS Combi Carba plus – for the detection of carbapenemase and OXA-48 enzyme production in Enterobacterales; and MAST ICT Indirect Carbapenemase Test – a screening test for the detection of carbapenemase production in Enterobacterales, Pseudomonas spp. and Acinetobacter spp.

Related Links:
Mast Group Ltd.


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Rapid Sepsis Test
SeptiCyte RAPID
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.